Clinical trials: Treatment Resistant Depressive Disorder
Treatment Resistant Depression
Neurobiological Analyses Within the FORESEE III Study
In this observational, non-invasive clinical study different neurobiological analyses will be performed in a group of patients with severe treatment resistant major depression participating in an efficacy study of deep brain…
- Trial name
- NCT04021823
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital Freiburg
Depressive Disorder, Treatment-Resistant
Psilocybin-assisted Interpersonal Therapy for Depression
This is a single-arm, open-label interventional study of psilocybin-assisted interpersonal therapy for treatment resistant depression.
- Trial name
- NCT05581797
- Testing
- Psilocybin-assisted psychotherapy
- Where
- New Zealand
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- University of Otago
Treatment Resistant Depression
Ketamine Frequency Treatment for Major Depressive Disorder
Depression is a wide spread illness. Depression contributes most significantly to national health care costs. While the number and types of treatments used for depression have expanded over the years, even with an increased range…
- Trial name
- NCT00646087
- Testing
- Ketamine, Ketamine/Saline
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Essentia Health
Depression, Treatment Resistant Depression
Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression
SHAKTI (from the Sanskrit word for "power") is a 5-year natural history, longitudinal, prospective study of a cohort of 6,000 participants that will help uncover the socio-demographic, lifestyle, clinical, psychological, and…
- Conditions
- Depression, Treatment Resistant Depression, Mood Disorders, Bipolar Disorder
- Trial name
- SHAKTI (NCT06002204)
- Testing
- Observational Study
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits
Most clinical major depression responds to standard treatments (medication and psychotherapy); however, a significant subset of depressed patients (15-20%) do not respond to these treatments and are referred to as…
- Trial name
- NCT02994433
- Testing
- Nitrous Oxide, MRI
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depression, Neurofeedback
Neurofeedback In Treatment Resistant Depression
The investigators evaluate the effects of neurofeedback as an augmentation treatment on depressive symptoms and functional recovery in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04078438
- Testing
- neurofeedback augmentation, treatment as usual
- Where
- South Korea
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Yeungnam University Hospital
Major Depression Moderate, Major Depression Severe
EEG Microstate and Neuroinflammatory Biomarkers in Older Age Patients With Major Depressive Disorder Receiving ECT
This study aims to investigate the neurophysiological and inflammatory changes associated with electroconvulsive therapy (ECT) in older age patients diagnosed with Major Depressive Episode, Major Depression, and Bipolar Disorder…
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression With Comorbid Anxiety Symptoms, Major Depression With Panic Attacks
- Trial name
- NCT07740694
- Testing
- Electroconvulsive Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Istanbul University - Cerrahpasa
Treatment Resistant Depression, Nitrous Oxyde
Brain Reactivity to Nitrous Oxyde in Depression : an MRI and Ultrasound Study (PROTOBRAIN Pilote)
Recent evidence suggest that Nitrous Oxyde (N2O) could exhibit antidepressant effect in treatment-resistant depression (TRD). However, the pathophysiology of this effect remains unclear and could include glutamatergic activity…
- Trial name
- NCT04199143
- Testing
- Nitrous Oxide-Oxygen, Tissue Pulsatility Imaging - TPI, Magnetic Resonance Imaging - MRI
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University Hospital, Tours
Treatment-resistant Depression
The Mechanisms of Underlying Accelerated Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression
In this project, the investigators evaluate an accelerated schedule of repetitive transcranial magnetic stimulation for treatment-resistant depression.
- Trial name
- NCT05607654
- Testing
- active iTBS
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital of Zhejiang University
Major Depressive Disorder
Dopaminergic Effects of Adjunctive Aripiprazole on the Brain in Treatment-Resistant Depression
Aripiprazole has been approved by the FDA for augmenting ineffective/partially effective oral antidepressant therapy in patients suffering from major depression. The mechanism by which this augmentation is achieved is not known.
- Trial name
- NCT00953745
- Testing
- Escitalopram, Aripiprazole
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Depression, Major Depressive Disorder
Reward Emotion Learning and Ketamine Study
Ketamine's efficacy as an antidepressant is now well established yet the mechanisms underlying its antidepressant effect are yet to be fully described.
- Conditions
- Depression, Major Depressive Disorder, Treatment Resistant Depression
- Trial name
- RELAKS (NCT04850911)
- Testing
- Ketamine Hydrochloride
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Late Life Depression
A Breathing-Based Meditation Intervention for Patients With Treatment Resistant Late Life Depression
Late-life depression affects 2-8% of seniors and causes high rates of caregiver distress and risk of suicide. To exacerbate the problem, antidepressants, the cornerstone of therapy, are resistant in 55-80% of this population.
- Trial name
- NCT03368560
- Testing
- Sudarshan Kriya Yoga
- Volunteers
- healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety Study of Escitalopram Augmentation in Treatment Resistant Schizophrenia
A primary hypothesis to be explored here is that, given its pharmacodynamic profile and hypothesized mechanisms associated with schizophrenia, escitalopram will, in comparison to placebo, be effective when added to risperidone or…
- Trial name
- NCT00231335
- Testing
- escitalopram
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Emory University
Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation
Comparison of the Efficacy of Accelerated Intermittent Theta Burst Stimulation and Accelerated Continuous Theta Burst Stimulation in Patients With Treatment-Resistant Depression
In recent years, research on the effectiveness of transcranial magnetic stimulation (TMS) in patients with treatment-resistant depression (RTD) has been steadily increasing.
- Conditions
- Treatment Resistant Depression (TRD), Transcranial Magnetic Stimulation, Accelerated Protocol, Intermittent Theta Burst Stimulation
- Trial name
- NCT07264452
- Testing
- Transcranial Magnetic Stimulation with figure-eight coil
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Ataturk University
PTSD, Alzheimer Disease
First-In-Human (FIH), Single Ascending Dose (SAD) Study of FluoroEthylNorMemantine (FENM)
The goal of this First-In-Human (FIH) trial is to learn about safety and PharmacoKinetics (PK) in healthy adult volunteers. The main questions it aims to answer are: What is the safety of single ascending doses of the…
- Conditions
- PTSD, Alzheimer Disease, Brain Diseases, Neuro-Degenerative Disease
- Trial name
- NCT05921929
- Testing
- Fluoroethylnormemantine (FENM)
- Where
- Belgium
- Volunteers
- healthy volunteers welcome
- Sponsor
- ReST Therapeutics
Treatment-Resistant Major Depressive Disorder
Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to Standard Treatment for Treatment-Resistant Major Depression in the Brazilian Public Health System (SUS)
Clinical trial aimed at evaluating whether a single infusion of tocilizumab, a medication that blocks the action of an inflammatory molecule called interleukin-6 (IL-6), can reduce symptoms of treatment-resistant major depression…
- Trial name
- NCT07052058
- Testing
- Tocilizumab, Normal Saline (0.9% NaCl)
- Where
- Brazil
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Hospital de Clinicas de Porto Alegre
Bipolar Depression
Treatment Resistant Bipolar Depression
To determine if adding Escitalopram to current mood stabilizer (MS) or atypical antipsychotic (AA) will improve in rates similar to or better than adding a placebo (inactive pill)in resistant bipolar patients.
- Trial name
- NCT00272025
- Testing
- Escitalopram
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Queen's University
Major Depressive Disorder, Depression
Investigating Predictors of Treatment Response in Treatment-Resistant Depression (TRD) With Interleaved TMS/fMRI
The purpose of this trial is identify biomarkers of response to repetitive transcranial magnetic stimulation (rTMS) in individuals with first episode or treatment resistant depression.
- Trial name
- NCT03642522
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of British Columbia
Unipolar Major Depression
Theta Burst Study Ghent
50 Right-handed antidepressant-free unipolar depressed patients (age 18-65 years) will be treated with in total 20 Theta burst sessions; these will be spread over 4 days.
- Trial name
- TBS Ghent (NCT01832805)
- Testing
- Theta burst stimulation.
- Where
- Belgium
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University Ghent
Healthy
A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers
This study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BCI-838 and its metabolite BCI-632 in healthy male and female subjects.
- Trial name
- NCT01548703
- Testing
- BCI-838
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.